Aurion Biotech
Aurion Biotech develops regenerative cell therapies for the treatment of blindness and vision loss, with a lead program focused on corneal endothelial cell therapy for patients with corneal endothelial disease. Its therapies aim to restore vision by replacing lost or dysfunctional endothelial cells using human donor cells, providing a less invasive alternative to traditional corneal transplantation. The organization’s mission is to expand global access to advanced ophthalmic care and address significant unmet needs in treating blindness.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology
- Founded
- 2022
- Employees
- 116
- Stage
- Clinical stage
- Members see funding amounts. .
Is this your organization? Claim it
week of june 10: Greg Kunst - Aurion Biotech
Top Stories 1. Microsoft CEO leaves Starbucks board Geekwire article 2. Seattle startup wins lawsuit against Boeing Seattle Times article 3. VC backed biotech Vilya raises $71M Geekwire article 4. Lightrail SLU location debate Opinion 1: The Stranger article Opinion 2: PSBJ article 5. New record store on Vashon Seattle Times article About guest co-host Greg Kunst - Founder & CEO, Aurion Biotech: Greg Kunst founded Aurion Biotech which is a company that develops cell therapies for the treatment of serious eye disorders. He is on the board of Pr3vent, Inc tackling vision health for babies. He's strategic advisor for…
People
-
Arnaud Lacoste Executive, Executive Officer, CEO and Chief Scientific Officer
-
Greg Kunst Executive, Executive Officer, Director, CEO